PL2837632T3 - Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych - Google Patents

Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych

Info

Publication number
PL2837632T3
PL2837632T3 PL13784533T PL13784533T PL2837632T3 PL 2837632 T3 PL2837632 T3 PL 2837632T3 PL 13784533 T PL13784533 T PL 13784533T PL 13784533 T PL13784533 T PL 13784533T PL 2837632 T3 PL2837632 T3 PL 2837632T3
Authority
PL
Poland
Prior art keywords
triazabicyclo
octane
derivatives
useful
treatment
Prior art date
Application number
PL13784533T
Other languages
English (en)
Inventor
Yongzhi Cheng
Zhi Cheng
Min Zhou
Zhaojun Wang
Huizhen Li
Shenggang Fan
Original Assignee
Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. filed Critical Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd.
Publication of PL2837632T3 publication Critical patent/PL2837632T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL13784533T 2012-04-13 2013-04-09 Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych PL2837632T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210109743 2012-04-13

Publications (1)

Publication Number Publication Date
PL2837632T3 true PL2837632T3 (pl) 2017-01-31

Family

ID=49514204

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13784533T PL2837632T3 (pl) 2012-04-13 2013-04-09 Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych

Country Status (7)

Country Link
US (1) US9090623B2 (pl)
EP (1) EP2837632B1 (pl)
JP (1) JP5925381B2 (pl)
KR (1) KR101673979B1 (pl)
CN (1) CN104334561B (pl)
PL (1) PL2837632T3 (pl)
WO (1) WO2013163917A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
EP3190112A4 (en) * 2014-09-04 2017-09-13 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124452A (en) 1978-07-10 1992-06-23 Bioresearch S.P.A. Process for producing d,1-5-methyltetrahydrofolic acid and its salts
CH681303A5 (pl) 1991-01-16 1993-02-26 Eprova Ag
DE4136921A1 (de) 1991-11-11 1993-05-13 Knoll Ag Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure
CH686369A5 (de) * 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
KR20040008175A (ko) 2001-05-14 2004-01-28 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로(10.3.1.02,11.04,9)-헥사데카-2(11),3,5,7,9-펜타엔의 시트르산염 및 그의 제약 조성물
DK1392307T3 (da) 2001-05-14 2005-11-07 Pfizer Prod Inc Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen
EP1461040B1 (en) 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
SI1448235T1 (sl) 2001-11-30 2007-08-31 Pfizer Prod Inc Peroralni farmacevtski sestavki s podaljšanim sproščanjem 5,8,14-triazatetraciklo (10.3.1.0(2,11).0(4,9)) -heksadeka-2(11)3,5,7,9-pentaena
SE0303526D0 (sv) * 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
CN101143863B (zh) * 2006-09-13 2010-08-11 南京莱因医药科技有限公司 5-甲基四氢叶酸的拆分及其成盐方法
DK2376499T3 (en) 2008-12-11 2015-05-04 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaencitratsalt
CN101781637B (zh) 2009-01-16 2012-09-05 中国科学院生物物理研究所 人源5,10-次甲基四氢叶酸合成酶及其复合物的结晶方法、晶体以及应用

Also Published As

Publication number Publication date
US9090623B2 (en) 2015-07-28
US20150065708A1 (en) 2015-03-05
WO2013163917A1 (zh) 2013-11-07
JP2015513360A (ja) 2015-05-11
JP5925381B2 (ja) 2016-05-25
CN104334561B (zh) 2016-06-22
EP2837632B1 (en) 2016-05-18
EP2837632A4 (en) 2015-10-14
CN104334561A (zh) 2015-02-04
EP2837632A1 (en) 2015-02-18
KR20140143437A (ko) 2014-12-16
KR101673979B1 (ko) 2016-11-08

Similar Documents

Publication Publication Date Title
HUS1900040I1 (hu) Makrociklusos származékok proliferatív betegségek kezelésére
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
SI2838539T1 (sl) Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
PL2837632T3 (pl) Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
HK1193343A (en) Methods for treating diseases of the retina
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL398695A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
HK1188955A (en) Methods for treating diseases of the retina
HK1189818A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
HK1197236B (en) Compounds for the treatment of addiction
HK1192488A (zh) 用作治疗法布瑞氏症的给药方案